Paper42903397PubMed
Anticoagulants beyond coagulation: repurposing heparin to mitigate immunothrombosis and inflammatory cascades in sepsis.
Ren Y and 10 others. Front Pharmacol, 2026.
Cite this record
ConductScience Library. Anticoagulants beyond coagulation: repurposing heparin to mitigate immunothrombosis and inflammatory cascades in sepsis. Papers, record 42903397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42903397
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Anticoagulants beyond coagulation: repurposing heparin to mitigate immunothrombosis and inflammatory cascades in sepsis.
- Journal
- Front Pharmacol
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-10-23
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References102
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37221630 | The pathophysiology, diagnosis, and management of sepsis-associated disseminated intravascular coagulation. | J Intensive Care | 2023 | https://conductscience.org/library/papers/37221630 | PubMed |
| 2 | 38245889 | International Consensus Criteria for Pediatric Sepsis and Septic Shock. | JAMA | 2024 | https://conductscience.org/library/papers/38245889 | PubMed |
| 3 | 38302978 | Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes. | Cardiovasc Diabetol | 2024 | https://conductscience.org/library/papers/38302978 | PubMed |
| 4 | 37958788 | Role of Neutrophil Extracellular Traps in Health and Disease Pathophysiology: Recent Insights and Advances. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37958788 | PubMed |
| 5 | 28561234 | Point-of-Care Testing in Acute Hemorrhagic and Thrombotic States. | Semin Thromb Hemost | 2017 | https://conductscience.org/library/papers/28561234 | PubMed |
| 6 | 39905519 | "The NET effect": Neutrophil extracellular traps-a potential key component of the dysregulated host immune response in sepsis. | Crit Care | 2025 | https://conductscience.org/library/papers/39905519 | PubMed |
| 7 | 26632486 | Neutralisation of the anti-coagulant effects of heparin by histones in blood plasma and purified systems. | Thromb Haemost | 2016 | https://conductscience.org/library/papers/26632486 | PubMed |
| 8 | 39334845 | The Preventive and Therapeutic Effects of Acute and Severe Inflammatory Disorders with Heparin and Heparinoid. | Biomolecules | 2024 | https://conductscience.org/library/papers/39334845 | PubMed |
| 9 | 38197931 | ICU-acquired infections in immunocompromised patients. | Intensive Care Med | 2024 | https://conductscience.org/library/papers/38197931 | PubMed |
| 10 | 39142741 | The burden and contemporary epidemiology of sepsis in children. | Lancet Child Adolesc Health | 2024 | https://conductscience.org/library/papers/39142741 | PubMed |
| 11 | 37359014 | Low-molecular-weight heparin therapy reduces 28-day mortality in patients with sepsis-3 by improving inflammation and coagulopathy. | Front Med (Lausanne) | 2023 | https://conductscience.org/library/papers/37359014 | PubMed |
| 12 | 26261772 | Heparin induced thrombocytopenia in critically ill: Diagnostic dilemmas and management conundrums. | World J Crit Care Med | 2015 | https://conductscience.org/library/papers/26261772 | PubMed |
| 13 | 41418999 | Damage-associated Molecular Patterns, Immunothrombosis, and Intravascular Inflammation in Sepsis: A Narrative Integrative Review. | Semin Thromb Hemost | 2025 | https://conductscience.org/library/papers/41418999 | PubMed |
| 14 | 33587773 | Heparanase expression and activity are increased in platelets during clinical sepsis. | J Thromb Haemost | 2021 | https://conductscience.org/library/papers/33587773 | PubMed |
| 15 | 34657233 | Unfractionated Heparin Attenuated Histone-Induced Pulmonary Syndecan-1 Degradation in Mice: a Preliminary Study on the Roles of Heparinase Pathway. | Inflammation | 2022 | https://conductscience.org/library/papers/34657233 | PubMed |
| 16 | 35047524 | Favorable Outcomes of Anticoagulation With Unfractioned Heparin in Sepsis-Induced Coagulopathy: A Retrospective Analysis of MIMIC-III Database. | Front Med (Lausanne) | 2021 | https://conductscience.org/library/papers/35047524 | PubMed |
| 17 | 36802946 | Effect of Anticoagulant Versus Non-Anticoagulant Therapy on Mortality of Sepsis-Induced Disseminated Intravascular Coagulation: A Systematic Review and Meta-Analysis. | Clin Appl Thromb Hemost | 2023 | https://conductscience.org/library/papers/36802946 | PubMed |
| 18 | 40904580 | Neutrophil extracellular traps in sepsis: trade-off between pros and cons. | Burns Trauma | 2025 | https://conductscience.org/library/papers/40904580 | PubMed |
| 19 | 35690822 | Clinical applications of machine learning in the survival prediction and classification of sepsis: coagulation and heparin usage matter. | J Transl Med | 2022 | https://conductscience.org/library/papers/35690822 | PubMed |
| 20 | 40221045 | Proteolytic neutralization of extracellular histones by neutrophil elastase is enhanced by heparin. | J Thromb Haemost | 2025 | https://conductscience.org/library/papers/40221045 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42903397
GET https://conductscience.org/api/papers/v1/42903397/references?page=2